topic

515 CD47 expression is upregulated in solid tumors and correlates with phagocytic tumor-associated macrophage gene signature
Nick van Buuren, Kelli Boyd, Mengshu Xu, Azadeh Madjidi, Christina Moon, Shiva Zaboli, Iris Liu, Ruidong Li, Kai-Hui Sun, Abhishek Aggarwal, Jared Odegard

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A581; DOI: 10.1136/jitc-2023-SITC2023.0515
516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3⁺/CD47⁺ tumors
Xinhua Wang, Oi Kwan Wong, Lei Shi, Qi Fei, Leonard Post, Xiaocheng Chen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A582; DOI: 10.1136/jitc-2023-SITC2023.0516
517 Blocking Siglec-7/9-sialic acid interactions induces immune cell-mediated suppression of prostate cancer
Ru Wen, Jessica Stark, George E Marti, Nicholas Riley, Hongjuan Zhao, Carolyn R Bertozzi, Sharon Pitteri, James D Brooks

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A583; DOI: 10.1136/jitc-2023-SITC2023.0517
518 Discovery of MACO-355, a novel, first in mechanism ligand-blocking independent anti-LILRB1/2 monoclonal antibody for cancer therapy
Krzysztof B Wicher, Moritz Haneklaus, Alicia Poindron, Martha Lopez-Yrigoyen, Carmen Rodriguez Seoane, Maikel Fransen, Chantell Payton, Stephane Guillame, Luca Cassetta, Stephen Myatt, Carola Ries

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A584; DOI: 10.1136/jitc-2023-SITC2023.0518
519 OR641 is a novel dual antagonist antibody that targets LILRB1 and LILRB2 inhibitory receptors and promotes a Th1-like immune response
Meghan Zuck, Kevin Green, Tatyana Pisarenko, Huyen Dinh, Myriam Bouchlaka, Francisco Zapata, Elsa L Hay, Gajendra Naika, Jacob Heit, Ray Fox, Darbie Whitman, Tom Graddis, Kamal D Puri, Peter Probst

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A585; DOI: 10.1136/jitc-2023-SITC2023.0519
520 Initial strategy of corticosteroids-immunosuppressant treatment and the consequent clinical outcome among non-small cell lung cancer patients with severe checkpoint inhibitor pneumonitis
Ting Mei, Youling Gong

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A586; DOI: 10.1136/jitc-2023-SITC2023.0520
521 mRNA encoded antibodies improve biodistribution and efficacy of checkpoint inhibitors for liver cancer
Shuo Wei, Melissa Mobley, Ran Tao, Yupeng Li, Sara Townsend, Alexa Vahey, Sonia Gregory, Yue Zhou, Jason Zhang, Stefano Gulla

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A587; DOI: 10.1136/jitc-2023-SITC2023.0521
522 Quantitative proteomic profiling of KZR-540, a novel small molecule oral Sec61 inhibitor that selectively inhibits PD-1 expression
David L Bade, Neel K Anand, Cristina Delgado Martin, Christopher Kirk, Yu Qian, Vaishnavi Beena Valsan, Jinhai Wang, Patricia Zuno-Mitchell

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A588; DOI: 10.1136/jitc-2023-SITC2023.0522
523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center
Jaanki Khandelwal, Devaki S Surasi, Sergio P Klimkowsky, Nathaniel Wilson, Mohammad J Moussa, Matthew Campbell, Amishi Shah, Eric Jonasch, Andrew Hahn, Elshad Hasanov, Jianjun Gao, Sangeeta Goswami, Pavlos Msaouel, Priya Rao, Kanishka Sircar, Nizar Tannir, Omar Alhalabi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A589; DOI: 10.1136/jitc-2023-SITC2023.0523
524 The association between mesothelial membranes metastasis and response to immune checkpoint inhibitors in solid tumors
Hassan Abushukair, Constantine Logothetis, Fawzi Abu Rous, Anwaar Saeed, Olivia Aranha, Moh’d Khushman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A590; DOI: 10.1136/jitc-2023-SITC2023.0524

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages